Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROQURE-1 concurrent EBRT + Lu-PSMA in node-positive prostate cancer
NL-OMON50800Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Maximum tolerated dose and Dose-limiting toxicity. Started Dec 2021; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON50800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50800.